Quince Therapeutics

What Quince Therapeutics does

Quince Therapeutics, Inc. is a South San Francisco-based, NASDAQ-listed (QNCX) late-stage biotechnology company developing therapeutics for rare diseases using its proprietary Autologous Intracellular Drug Encapsulation (AIDE) platform. The AIDE technology is an automated drug/device combination that encapsulates drugs into a patient's own red blood cells using a CE-marked RCL (Red Cell Loader) automated point-of-care device paired with a CE-marked single-use sterile treatment kit (EryKit), designed to improve biodistribution, prolong circulating half-life, and reduce immunogenicity for small molecules, large molecules, peptides, proteins, and biologics.

The lead clinical asset, eDSP (encapsulated dexamethasone sodium phosphate, formerly EryDex), applied the AIDE platform to corticosteroid delivery and was developed primarily for Ataxia-Telangiectasia and Duchenne Muscular Dystrophy, with a publicly disclosed list of eleven additional rare disease indications being pursued via licensing. The pivotal Phase 3 NEAT trial of eDSP in Ataxia-Telangiectasia failed its primary endpoint in January 2026, prompting a strategic alternatives process and severe financial distress. In May 2026, Quince acquired Orphai Therapeutics and added LAM-001, an inhaled rapamycin product with U.S. and EU orphan drug designations targeting Pulmonary Arterial Hypertension and Pulmonary Hypertension associated with Interstitial Lung Disease, currently in Phase 2.

Quince generates no current revenue and operates a pre-commercial licensing-and-partnership revenue model: business development outreach ([email protected]) is the primary commercial channel, supplemented by an enterprise advisor-led motion via LifeSci Capital. The company has grown primarily through acquisitions (Novosteo 2022, EryDel 2023, Orphai 2026) and has been funded through a combination of post-IPO equity and pre-IPO venture rounds totaling over $360 million historically, with an up to $187 million private placement announced alongside the Orphai deal to fund the integrated pulmonary pipeline.

Name

Quince Therapeutics

Legal name

Quince Therapeutics, Inc.

Website

https://quincetx.com

Company type

Public

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Quince Therapeutics is a NASDAQ-listed, late-stage rare disease biotech developing drug/device therapies based on its proprietary AIDE red blood cell encapsulation platform, with a lead Phase 3-failed asset (eDSP) and a newly acquired inhaled rapamycin program (LAM-001) for pulmonary disorders.

Ownership category

akta.pro rank

Product category

Rare Disease Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

CRISPR & Functional Genomics Screening Platforms (pooled/arrayed screens, perturb-seq) (HLAAAIAG)

Keywords

• Rare disease therapeutics
• Drug delivery platform
• Red blood cell encapsulation
• Autologous drug device combination
• Clinical stage biotechnology

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Others

Revenue model

1. No current revenue: Quince Therapeutics reports no revenue. The company is pre-commercial, with a negative EPS of -10.62 (as of May 2026) and product candidates still in clinical development or recently failed trials.
2. Future licensing royalties (planned): The Pipeline page invites inbound licensing inquiries via [email protected] for eDSP across additional indications (DMD and prioritized rare disease targets such as autoimmune hepatitis, pulmonary sarcoidosis, dermatomyositis, pemphigus vulgaris, Hashimoto's encephalopathy, Becker muscular dystrophy, pediatric lupus, juvenile idiopathic arthritis, myasthenia gravis, limb-girdle muscular dystrophy, and chronic inflammatory demyelinating polyradiculoneuropathy). Implies a future licensing/royalty revenue model contingent on regulatory approval.

Go-to-market motion2 records

Core offering

Quince Therapeutics is a late-stage, pre-commercial biotechnology company developing drug/device combination therapeutics for rare diseases using its proprietary AIDE (Autologous Intracellular Drug Encapsulation) platform. The AIDE platform pairs the CE-marked RCL (Red Cell Loader) automated device with a CE-marked sterile single-use treatment kit to encapsulate drugs inside a patient's own red blood cells at the point of care in approximately two hours. Its lead clinical-stage product eDSP (encapsulated dexamethasone sodium phosphate) is being developed for Ataxia-Telangiectasia and Duchenne Muscular Dystrophy, and the company added the inhaled rapamycin product LAM-001 for rare pulmonary disorders via its May 2026 acquisition of Orphai Therapeutics.

Product overview

Quince Therapeutics operates a single integrated product architecture centered on its proprietary AIDE (Autologous Intracellular Drug Encapsulation) technology platform, which pairs the CE-marked RCL (Red Cell Loader) automated device with a CE-marked single-use treatment kit to encapsulate drugs into a patient's own red blood cells at the point of care. The lead clinical-stage product eDSP (encapsulated dexamethasone sodium phosphate, formerly EryDex, acquired via the 2023 EryDel acquisition) is the first drug to leverage this platform, with clinical programs in Ataxia-Telangiectasia (lead indication, Phase 3 NEAT failed in February 2026) and Duchenne Muscular Dystrophy (second indication, Phase 2 study designs finalized). The platform architecture and underlying RCL/EryKit consumables support broader indication expansion (autoimmune hepatitis, pulmonary sarcoidosis, dermatomyositis, pemphigus vulgaris, Hashimoto's encephalopathy, Becker muscular dystrophy, pediatric lupus, juvenile idiopathic arthritis, myasthenia gravis, limb-girdle muscular dystrophy, and chronic inflammatory demyelinating polyradiculoneuropathy). In May 2026 Quince expanded its portfolio through the acquisition of Orphai Therapeutics, adding the inhaled rapamycin product LAM-001 for rare pulmonary disorders (PAH and PH-ILD). The 2022 Novosteo acquisition and corporate rebrand from Cortexyme to Quince Therapeutics completed the pipeline focus on rare-disease therapeutics.

Differentiator

Problem solved

Functional benefit

Brands

• AIDE (Autologous Intracellular Drug Encapsulation): Proprietary drug/device combination technology platform that encapsulates drugs into a patient's own red blood cells using the RCL device and single-use treatment kit.
• eDSP

Products and services

• AIDE Technology Platform (Autologous Intracellular Drug Encapsulation) Proprietary drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, designed to harness benefits including potentially better tolerability, enhanced tissue biodistribution, reduced immunogenicity, and prolongation of circulating half-life; applicable to small molecules, large molecules, peptides, proteins, and biologics.
• eDSP (encapsulated Dexamethasone Sodium Phosphate; previously EryDex) First product leveraging the AIDE technology platform, composed of dexamethasone sodium phosphate (DSP) encapsulated in autologous red blood cells; designed to maintain corticosteroid efficacy while reducing or eliminating chronic toxicity such as adrenal suppression, with lead development in Ataxia-Telangiectasia and Duchenne Muscular Dystrophy.
• RCL (Red Cell Loader) Device Proprietary CE-marked non-invasive automated device that performs blood processing at the point of care to automate the AIDE encapsulation process; features a touchscreen interface with three microprocessor circuit boards and handles blood, drug, and processing solutions using the single-use treatment kit.
• Single-Use Treatment Kit (EryKit consumables) CE-marked sterile, single-use, pyrogen-free disposable blood tubing system used with the RCL to encapsulate small molecules, large molecules, and biologics into human red blood cells; contains a centrifuge, hemoconcentrator filter, bags, organizer cassette, and accessories.
• LAM-001 (inhaled formulation of rapamycin) Inhaled formulation of rapamycin targeting rare pulmonary disorders including Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD); holds U.S. and EU orphan drug designations across multiple indications.

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Liquidia Technologies: Commercial-stage company with YUTREPIA, an inhaled treprostinil for PAH/PH-ILD, putting it in direct therapeutic-area competition with Quince's LAM-001 program.
• EryTech Pharma: French biotech that develops red blood cell-encapsulated therapeutics (eryaspase, Graspa) — historically the closest direct peer to Quince's AIDE red-cell encapsulation platform, focused on rare metabolic and oncology indications.
• Gossamer Bio: Late-stage clinical biotech developing seralutinib for PAH; a direct competitor in the rare pulmonary hypertension space where LAM-001 is being positioned.

Broad incumbents

• Ultragenyx Pharmaceutical: Established rare-disease biotech with multiple approved products and a broad rare-disease pipeline; a natural strategic acquirer/partner comparable for Quince given its rare-disease focus and clinical-stage assets.
• United Therapeutics: Commercial leader in PAH (Tyvaso, Remodulin, Orenitram) and a key competitor for any inhaled pulmonary asset; relevant comparator for LAM-001's commercial potential in PAH and PH-ILD.
• BioMarin Pharmaceutical: Major rare-disease commercial player (Naglazyme, Vimizim, Voxzogo, Roctavian) with a long history of orphan drug development and acquisitions of late-stage rare-disease assets — relevant benchmark and potential acquirer profile.
• Alexion (AstraZeneca Rare Disease): Established rare-disease franchise within AstraZeneca (Soliris, Ultomiris, Strensiq); a benchmark for rare-disease commercial execution and a potential acquirer/partner for AIDE-derived programs.
• Swedish Orphan Biovitrum (Sobi): Specialty rare-disease biopharma with a portfolio that includes corticosteroids and inflammatory/immunology indications overlapping with the eDSP pipeline expansion list (DMD, JIA, autoimmune diseases).

Emerging players

• Edgewise Therapeutics: Clinical-stage biotech focused on rare muscle disorders including Duchenne and Becker muscular dystrophy — directly comparable for Quince's eDSP DMD/Becker MD programs.
• Insmed: Rare pulmonary-disease biotech (approved ARIKAYCE for MAC lung disease and a Phase 3 program in PH-ILD); comparable business model and therapeutic focus to LAM-001's PAH/PH-ILD positioning.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/cortexyme
• YouTubeyoutube.com/@QuinceTherapeutics
• Facebookfacebook.com/people/Quince-Therapeutics/61554791232046
• LinkedInlinkedin.com/company/quincetx-inc

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Subsidiaries3 records

Funding overview

Funding rounds8 records

Investors30 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quince Therapeutics